AIxBio RegistryAI molecules in the clinic

About

The registry

The AIxBio Registry is an open registry of drug candidates whose target or molecule was materially shaped by AI or machine learning and that have been given to people. Each entry is counted against a written definition (methodology), sourced row by row, and open to correction. The data are free to reuse under CC BY 4.0, and download from the foot of the home page; every release is listed in the changelog.

It exists because published counts of "AI-discovered drugs" disagree, and most do not say what they counted or let anyone check. It began as the evidence base for Turning the Crank Faster, an essay on AI in drug discovery for Backed By Reality, John E. Milad's Substack (2 November 2026). It has been public since 20 October 2026. Version 1.0 was released on 2 November 2026; entries are revised as the evidence changes, and every release is in the changelog.

Who maintains it

John E. Milad is a life sciences executive and investor based in the UK, with more than 25 years across operating roles, venture capital and investment banking in biotech, MedTech and healthcare technology. He brings an operator-investor's perspective to how new science becomes products and companies, and writes about AI, healthcare and innovation on his Substack, Backed By Reality.

He is CEO of ERS Genomics, which licenses foundational CRISPR/Cas9 intellectual property worldwide outside direct human therapeutics. He is also a non-executive director of Northern Venture Trust, a venture capital trust, and a trustee of Kidney Research UK. Before ERS Genomics he was CEO of Quanta Dialysis Technologies for eight years, taking it from early-stage R&D to a transatlantic commercial company that won the Royal Academy of Engineering's MacRobert Award in 2022. Earlier he worked in venture capital (NBGI Ventures, Atlas Venture, Downing LLP), private equity (Kirkland Investors) and investment banking (Lehman Brothers, Nomura).

The registry is a personal project. It is independent of ERS Genomics and of every developer it lists, and no one paid for it. Find John on LinkedIn, Substack and ORCID (publications and patents), or email aixbio.registry@outlook.com.

How it was built

AI agents did the searching, the blind coding of each entry, the red-team challenges and the re-checking of quotes. John made every judgement call the written rules did not settle, and reviewed and signed off each entry in the strict count. No independent expert has reviewed the registry yet; reviewers will be named here when they have. The full account is in the methodology.

Corrections

Anyone can propose a correction or a missing molecule with the corrections form. Each submission is checked against its sources and the methodology, and the outcome is published in the corrections log. Names and email addresses given with a correction are never published.

The chatbot

"Ask the registry" answers questions from the registry's data, its methodology, this page, its background notes and the text of the sources it cites, and links to them. Numbers are computed from the data, not by the model. It runs on Claude Haiku 5.5 (Anthropic), chosen on a test of questions whose answers are computed from the data. It can be wrong, so check the linked entry; it gives no medical or investment advice. Each visitor can ask 10 questions an hour and 30 a day. Questions and the chatbot's answers are kept for 30 days to check answer quality, then deleted; no names or accounts are needed.

Disclaimer

The registry is provided as is, for information and research. It is not medical, investment or legal advice. Entries are compiled from public sources and may be incomplete or wrong: check the cited sources before relying on any entry, and send a correction if you find an error. Listing a molecule is not a rating of its safety or efficacy, nor an endorsement of it or its developer. Product and company names belong to their owners. The views here are the maintainer's own, not those of ERS Genomics or of any other organization the maintainer works with. As far as the law allows, the maintainer accepts no liability for decisions made using the registry. How personal data is handled is set out on the privacy page.

Citing

Use the citation at the foot of the home page, which gives the current version and data date.